This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Sunitinib
From Proteopedia
(Difference between revisions)
(New page: ===Pharmacokinetics=== {| class="wikitable" border="1" width="40%" style="text-align:center" |- ! colspan="6" align="center"| VEGFR Inhibitor [[Pharmaceutical_Drugs#Pharmacokinetics_Tran...) |
|||
| Line 1: | Line 1: | ||
| - | === | + | <applet load="" size="480" color="" frame="true" spin="on" Scene ="" align="right" caption="Sunitinib, also known as Sutent, ([[2rlf]])"/> |
| + | ===Better Known as: Sutent=== | ||
| + | * Marketed By: Pfizer<br /> | ||
| + | * Major Indication: [[Influenza]] Infection<br /> | ||
| + | * Drug Class: [[M2 Proton Channel]] Inhibitor | ||
| + | * Date of FDA Approval (Patent Expiration): 2006 (2001)<br /> | ||
| + | * 1994 Sales: N/A | ||
| + | * Importance: One of the the first treatments for [[Influenza]] Infections. Since 1994, nearly 100% of influenza viruses had developed resistance to rimantadine, and it is no longer recommended as a treatment for the flu. | ||
| + | * See [[Pharmaceutical Drugs]] for more information about other drugs and disorders. | ||
| + | ===Mechanism of Action=== | ||
| + | |||
| + | ===Pharmacokinetics=== | ||
{| class="wikitable" border="1" width="40%" style="text-align:center" | {| class="wikitable" border="1" width="40%" style="text-align:center" | ||
|- | |- | ||
| Line 41: | Line 52: | ||
! Hepatic (CYP3A4) | ! Hepatic (CYP3A4) | ||
|} | |} | ||
| + | |||
| + | ===References=== | ||
| + | <references/> | ||
| + | __NOEDITSECTION__ | ||
| + | __NOTOC__ | ||
Revision as of 12:08, 9 December 2010
|
Better Known as: Sutent
- Marketed By: Pfizer
- Major Indication: Influenza Infection
- Drug Class: M2 Proton Channel Inhibitor
- Date of FDA Approval (Patent Expiration): 2006 (2001)
- 1994 Sales: N/A
- Importance: One of the the first treatments for Influenza Infections. Since 1994, nearly 100% of influenza viruses had developed resistance to rimantadine, and it is no longer recommended as a treatment for the flu.
- See Pharmaceutical Drugs for more information about other drugs and disorders.
Mechanism of Action
Pharmacokinetics
| VEGFR Inhibitor Pharmacokinetics [1][2][3][4][5] | |||||
|---|---|---|---|---|---|
| Parameter | Sunitinib (Sutent) | Sorafenib (Nexavar) | |||
| Tmax (hr) | 8 | 8.3 | |||
| Cmax (ng/ml) | 24.6 | 460 | |||
| Bioavailability (%) | Variable | 29-49 | |||
| Protein Binding (%) | 95 | 99 | |||
| T1/2 (hr) | 83 | 29 | |||
| AUC (ng/ml/hr) | 1921 | 11040 | |||
| Dosage (mg) | 50 | 50 | |||
| Metabolism | Hepatic (CYP3A4) | Hepatic (CYP3A4) | |||
References
- ↑ D. Smith et al. Br J Clin Pharmacol. 2009 April; 67(4): 421–426.
- ↑ R. Khosravan, et al. General Poster Session, Developmental Therapeutics: Cytotoxic Chemotherapy, J Clin Oncol 26: 2008 (May 20 suppl; abstr 2578)
- ↑ Lathia C, Lettieri J, Cihon F, Gallentine M, Radtke M, Sundaresan P. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol. 2006 May;57(5):685-92. Epub 2005 Aug 25. PMID:16133532 doi:10.1007/s00280-005-0068-6
- ↑ Brendel E, Ludwig M, Lathia C, Robert C, Ropert S, Soria JC, Armand JP. Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2010 Sep 7. PMID:20821331 doi:10.1007/s00280-010-1423-9
- ↑ Boven E, Massard C, Armand JP, Tillier C, Hartog V, Brega NM, Countouriotis AM, Ruiz-Garcia A, Soria JC. A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours. Br J Cancer. 2010 Sep 28;103(7):993-1000. Epub 2010 Aug 17. PMID:20717111 doi:10.1038/sj.bjc.6605852
